A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Oscotec Inc.
Instituto do Cancer do Estado de São Paulo
University of Iowa
AstraZeneca
Jonsson Comprehensive Cancer Center
IDEAYA Biosciences
National Cancer Institute (NCI)
Tufts Medical Center
Emory University
Sumitomo Pharma America, Inc.
Trishula Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Weill Medical College of Cornell University
Eli Lilly and Company
University of California, San Diego
The Netherlands Cancer Institute
Medical University of South Carolina
University of Nebraska
Canadian Cancer Trials Group
University of California, Davis
Calithera Biosciences, Inc
Weill Medical College of Cornell University
NanOlogy, LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
Takeda
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Duke University
Medical University of South Carolina
SWOG Cancer Research Network
University of Michigan Rogel Cancer Center
Columbia University
University of Arizona
AmpliMed Corporation
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
Centocor, Inc.
Synta Pharmaceuticals Corp.
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
AstraZeneca
Emory University
GlaxoSmithKline
Case Comprehensive Cancer Center
National Cancer Institute, Naples
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins